

**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JOINT STOCK
COMPANY**

No.: 07/2025/CV-MED

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, January 20, 2025

To: - **State Securities Commission**
 - **Hanoi Stock Exchange**

Company Name: Mediplantex National Pharmaceutical Joint Stock Company

Address: 358 Giai Phong, Phuong Liet Ward, Thanh Xuan District, Hanoi

Tax code: 0100108430

Information disclosure person: Mai Nhat Thanh

Position: General Director

Pursuant to Circular No. 96/2020/TT-BTC of the Ministry of Finance on periodic information disclosure of organizations, specific explanations are provided for cases where after-tax profits differ by 10% compared to the same period last year.

Mediplantex National Pharmaceutical Joint Stock Company explains the financial statements for the fourth quarter of 2024 as follows:

- Net revenue from sales of good and rendering of service in the fourth quarter of 2024 were VND 105,919,940,676, decreased by 5%. Gross profit VND 23,039,192,266 decreased by 2% compared to the same period in the fourth quarter of 2023.

- Revenue from financial activities were VND 521,090,709 decreased by 77% compared to the same period last year due to the company paying money to partners. Interest expense was 1,355,782,491 VND decreased by 27% because the company recovered debts well, the average loan was lower than last year.

- By changing the sales policy, the Board of Management has reduced sales expenses to VND 1,294,917,859, a decrease of 67% compared to the same period last year.

- In addition, business management costs were VND 17,024,673,523 increased by 15%. Therefore, net profit from business activities was VND 3,884,909,102, decreased by 26% compared to the same period last year.

- The above factors have caused the profit after corporate income tax VND which was VND 2,903,224,364 decreased 29,6% compared to the same period in the fourth quarter of 2023.

Above is the explanation of Mediplantex National Pharmaceutical Joint Stock Company reporting to the State Securities Commission and Hanoi Stock Exchange on the change of indicators in the financial report of the fourth quarter of 2024 compared to the financial report of the same period last year of Mediplantex National Pharmaceutical Joint Stock Company.

Best regards!

Recipient:

- As above
- Admin

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT

STOCK COMPANY

GENERAL DIRECTOR

